GS-9451 in Treatment Naïve Subjects with Chronic Genotype 1 HCV.

• Research type

  Research Study

• Full title

  A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Escalating, Multiple, Oral Doses of GS-9451 in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS-US-169-0119)

• IRAS ID

  33818

• Sponsor organisation

  Gilead Sciences, Inc

• Eudract number

  2009-015061-31

• ISRCTN Number

  n.a

• Clinicaltrials.gov Identifier

  n.a

• Research summary

  N/A

• REC name

  East of England - Cambridge East Research Ethics Committee

• REC reference

  09/H0304/84

• Date of REC Opinion

  30 Dec 2009

• REC opinion

  Further Information Favourable Opinion